In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead (GILD 0.58%) for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.
Gilead Keeps on Building
By Dave Williamson – Mar 22, 2013 at 9:02PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$147B
Today's Change
(-0.58%) $0.69
Current Price
$118.15
Price as of November 10, 2025 at 4:00 PM ET
One more step towards Gilead's HIV treatment empire.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid